JP2017527563A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527563A5
JP2017527563A5 JP2017512775A JP2017512775A JP2017527563A5 JP 2017527563 A5 JP2017527563 A5 JP 2017527563A5 JP 2017512775 A JP2017512775 A JP 2017512775A JP 2017512775 A JP2017512775 A JP 2017512775A JP 2017527563 A5 JP2017527563 A5 JP 2017527563A5
Authority
JP
Japan
Prior art keywords
ala
carbon atoms
optionally substituted
val
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527563A (ja
JP6606545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048059 external-priority patent/WO2016036801A1/en
Publication of JP2017527563A publication Critical patent/JP2017527563A/ja
Publication of JP2017527563A5 publication Critical patent/JP2017527563A5/ja
Application granted granted Critical
Publication of JP6606545B2 publication Critical patent/JP6606545B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512775A 2014-09-03 2015-09-02 細胞障害性ベンゾジアゼピン誘導体 Expired - Fee Related JP6606545B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462045248P 2014-09-03 2014-09-03
US62/045,248 2014-09-03
US201462087040P 2014-12-03 2014-12-03
US62/087,040 2014-12-03
US201562149370P 2015-04-17 2015-04-17
US62/149,370 2015-04-17
US201562164305P 2015-05-20 2015-05-20
US62/164,305 2015-05-20
PCT/US2015/048059 WO2016036801A1 (en) 2014-09-03 2015-09-02 Cytotoxic benzodiazepine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019192174A Division JP6802340B2 (ja) 2014-09-03 2019-10-21 細胞障害性ベンゾジアゼピン誘導体

Publications (3)

Publication Number Publication Date
JP2017527563A JP2017527563A (ja) 2017-09-21
JP2017527563A5 true JP2017527563A5 (OSRAM) 2019-10-03
JP6606545B2 JP6606545B2 (ja) 2019-11-13

Family

ID=54140691

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017512775A Expired - Fee Related JP6606545B2 (ja) 2014-09-03 2015-09-02 細胞障害性ベンゾジアゼピン誘導体
JP2019192174A Expired - Fee Related JP6802340B2 (ja) 2014-09-03 2019-10-21 細胞障害性ベンゾジアゼピン誘導体
JP2020195666A Active JP7132311B2 (ja) 2014-09-03 2020-11-26 細胞障害性ベンゾジアゼピン誘導体
JP2022133442A Ceased JP2022166293A (ja) 2014-09-03 2022-08-24 細胞障害性ベンゾジアゼピン誘導体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019192174A Expired - Fee Related JP6802340B2 (ja) 2014-09-03 2019-10-21 細胞障害性ベンゾジアゼピン誘導体
JP2020195666A Active JP7132311B2 (ja) 2014-09-03 2020-11-26 細胞障害性ベンゾジアゼピン誘導体
JP2022133442A Ceased JP2022166293A (ja) 2014-09-03 2022-08-24 細胞障害性ベンゾジアゼピン誘導体

Country Status (33)

Country Link
US (5) US9669102B2 (OSRAM)
EP (2) EP3189056B1 (OSRAM)
JP (4) JP6606545B2 (OSRAM)
KR (2) KR102632830B1 (OSRAM)
CN (2) CN106604927B (OSRAM)
AU (3) AU2015311987B2 (OSRAM)
BR (1) BR112017002963A2 (OSRAM)
CA (1) CA2959630A1 (OSRAM)
CL (1) CL2017000507A1 (OSRAM)
CO (1) CO2017003011A2 (OSRAM)
CR (1) CR20170111A (OSRAM)
CY (1) CY1123325T1 (OSRAM)
DK (1) DK3189056T3 (OSRAM)
DO (1) DOP2017000053A (OSRAM)
EA (1) EA034138B1 (OSRAM)
EC (1) ECSP17020133A (OSRAM)
ES (1) ES2815353T3 (OSRAM)
HU (1) HUE051002T2 (OSRAM)
IL (4) IL250712B (OSRAM)
LT (1) LT3189056T (OSRAM)
MA (1) MA54254A (OSRAM)
MX (1) MX2017002758A (OSRAM)
PE (1) PE20170775A1 (OSRAM)
PH (1) PH12017500358A1 (OSRAM)
PL (1) PL3189056T3 (OSRAM)
PT (1) PT3189056T (OSRAM)
RS (1) RS60751B1 (OSRAM)
SG (2) SG10201901824UA (OSRAM)
SI (1) SI3189056T1 (OSRAM)
SM (1) SMT202000449T1 (OSRAM)
TN (1) TN2017000070A1 (OSRAM)
TW (4) TW202417447A (OSRAM)
WO (1) WO2016036801A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160058884A1 (en) * 2014-09-02 2016-03-03 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TW202417447A (zh) 2014-09-03 2024-05-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
LT3313884T (lt) * 2015-06-29 2021-03-10 Immunogen, Inc. Anti-cd123 antikūnai, konjugatai ir jų dariniai
EP3653628B1 (en) * 2015-07-21 2022-09-14 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
FI3380525T3 (fi) 2015-11-25 2024-01-30 Immunogen Inc Lääkeformulaatioita ja niiden käyttömenetelmiä
CN108883196A (zh) * 2016-02-05 2018-11-23 米伦纽姆医药公司 靶向gcc的抗体-药物缀合物
WO2018098258A2 (en) * 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
CN110267685B (zh) 2016-12-23 2023-06-20 伊缪诺金公司 靶向adam9的免疫缀合物及其使用方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
IL305224B2 (en) 2017-04-20 2024-09-01 Immunogen Inc Methods of preparing indolinobenzodiazepine derivatives
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021506883A (ja) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピン抗体結合体
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
KR20220022112A (ko) * 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
CA3139180A1 (en) * 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CA3154072A1 (en) 2019-09-13 2021-03-18 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
EP4548932A1 (en) 2022-06-30 2025-05-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453266A (en) 1966-03-14 1969-07-01 American Home Prod 1,2,5-benzothiadiazepine 1,1-dioxides
US3506646A (en) 1966-06-27 1970-04-14 American Home Prod Process for the preparation of 7h-pyrido (1,2-b)(1,2,5)benzothiadiazepine 5,5 - dioxides and pyrrolo(1,2-b)(1,2,5)benzothiadiazepine 5,5-dioxides
US3875162A (en) 1973-07-26 1975-04-01 Squibb & Sons Inc Certain 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 benzothiadiaza compounds
US4003905A (en) 1974-12-11 1977-01-18 E. R. Squibb & Sons, Inc. Diels-alder adducts of benzdiazepines
US4444688A (en) 1981-05-11 1984-04-24 Ciba-Geigy Corporation Imidazobenzothiadiazepines
JP2920385B2 (ja) 1988-08-18 1999-07-19 武田薬品工業株式会社 1,2,5‐ベンゾチアジアゼピン誘導体,その製造法および用途
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体(ポリ)ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
US6156746A (en) 1998-08-25 2000-12-05 Bristol-Myers Squibb Company 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
DK1413582T3 (da) 1998-08-27 2006-07-17 Spirogen Ltd Dimere pyrrolobenzodiazepiner
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
FR2850654A1 (fr) 2003-02-03 2004-08-06 Servier Lab Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004240541B2 (en) 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
EP1660513B9 (en) 2003-07-21 2012-04-04 ImmunoGen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
ATE516288T1 (de) * 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
EP3225633B1 (en) 2004-05-21 2020-03-25 The UAB Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
DE602006010386D1 (en) 2005-07-08 2009-12-24 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
US7772485B2 (en) 2005-07-14 2010-08-10 Konarka Technologies, Inc. Polymers with low band gaps and high charge mobility
ITRM20050416A1 (it) 2005-08-03 2007-02-04 Uni Degli Studi Di Roma Tor Vergata Derivati delle benzodiazepine e loro usi in campo medico.
BRPI0520509A2 (pt) 2005-08-22 2009-05-12 Immunogen Inc anticorpo ou seu fragmento de ligação de epitopo, polinucleotìdeo, célula hospedeira, e método de preparação de um anticorpo ou seu fragmento de ligação de epitopo
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
WO2007098611A1 (en) 2006-03-03 2007-09-07 Queen's University At Kingston Compositions for treatment of cancer
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
US8301398B2 (en) 2006-06-22 2012-10-30 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
MX2010011808A (es) 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
EP3100745B1 (en) * 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
CN106046159B (zh) 2010-03-12 2020-06-16 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
PT2571531T (pt) 2010-04-30 2016-08-31 Janssen Biotech Inc Composições do domínio da fibronectina estabilizadas, métodos e utilizações
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
EP2675479B1 (en) 2011-02-15 2016-01-13 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
UA125636C2 (uk) 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
KR101762047B1 (ko) * 2012-11-05 2017-07-27 화이자 인코포레이티드 스플라이세오스타틴 유사체
TW202417447A (zh) 2014-09-03 2024-05-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
TW201609152A (zh) * 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物

Similar Documents

Publication Publication Date Title
JP2017527563A5 (OSRAM)
CN118434765A (zh) Bcma单克隆抗体和抗体-药物偶联物
JP2014521591A5 (OSRAM)
RU2017144859A (ru) Конъюгаты сконструированных антител с цистеиновыми заменами
AU2016279051B2 (en) Delivery systems for controlled drug release
CN113423430B (zh) 含支链连接子的鹅膏毒素偶联物
JP2021527040A (ja) カンプトテシンコンジュゲート
HRP20160164T1 (hr) Citotoksiäśni derivati benzodiazepina
JP2021500412A (ja) 単一分子量ポリサルコシンを含むリガンド−薬物−複合体
JP2015508074A5 (OSRAM)
JP2017529837A5 (OSRAM)
HRP20230275T1 (hr) Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina
RU2020123953A (ru) Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
RU2017110068A (ru) Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты
JP2018528162A5 (OSRAM)
JP2019512492A (ja) Peg化薬物リンカー及びその中間体を調製するためのプロセス
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
IL308504A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL273384B2 (en) Methods of preventing methionine oxidation in immunoconjugates
CN120835792A (zh) 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤
ES2981742T3 (es) Conectores para-amino-bencilo, proceso para su preparación y su uso en conjugados
US20240269313A1 (en) Conjugates comprising a phosphorus(v) moiety and a drug
HK40069235A (en) Delivery systems for controlled drug release
TW202529814A (zh) 用於綴合之化合物、綴合物及包含其之醫藥組成物